​

Travere Therapeutics Ownership | Who Owns Travere Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Travere Therapeutics Ownership Summary

Travere Therapeutics is owned by 106.26% institutional investors, 0.65% insiders. Blackrock is the largest institutional shareholder, holding 9.86% of TVTX shares. Delaware Small Cap Core I is the top mutual fund, with 4.42% of its assets in Travere Therapeutics shares.

TVTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTravere Therapeutics106.26%0.65%-6.92%
SectorHealthcare Stocks 88.01%8.90%3.09%
IndustryBiotech Stocks 109.70%8.77%-18.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock7.64M9.86%$62.84M
Armistice capital7.50M9.68%$61.65M
Deep track capital, lp7.37M9.51%$60.58M
Vanguard group6.62M8.54%$54.41M
Rock springs capital management lp4.48M5.78%$36.84M
Macquarie group4.37M5.64%$35.90M
State street3.51M4.53%$28.86M
Morgan stanley3.49M4.50%$28.69M
Millennium management2.95M3.81%$24.24M
Renaissance2.20M2.84%$18.12M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Finepoint capital lp1.78M4.15%$14.60M
Deep track capital, lp7.37M1.81%$60.58M
Kynam capital management, lp2.02M1.28%$16.62M
Rock springs capital management lp4.48M1.11%$36.84M
Parkman healthcare partners969.89K1.07%$7.97M
Birchview capital, lp122.00K0.93%$1.00M
Knott david m jr265.97K0.87%$2.19M
Armistice capital7.50M0.78%$61.65M
Highvista strategies219.42K0.66%$1.80M
Eversept partners, lp1.09M0.61%$8.97M

Top Buyers

HolderShares% AssetsChange
Woodline partners lp1.28M0.10%1.28M
Rock springs capital management lp4.48M1.11%1.06M
Jennison associates816.40K0.01%816.40K
Jacobs levy equity management1.89M0.06%765.16K
Millennium management2.95M0.01%747.41K

Top Sellers

HolderShares% AssetsChange
State street3.51M0.00%-3.10M
Deutsche bank ag\946.60K0.00%-1.45M
Pictet asset management sa977.95K0.01%-1.26M
Assenagon asset management530.51K0.01%-844.01K
Renaissance2.20M0.03%-658.20K

New Positions

HolderShares% AssetsChangeValue
Jennison associates816.40K0.01%816.40K$14.22M
Abrdn392.00K0.01%392.00K$6.83M
Trexquant investment lp174.49K0.02%174.49K$1.43M
Norges bank71.00K0.00%71.00K$583.62K
Hudson bay capital management lp44.56K0.00%44.56K$366.29K

Sold Out

HolderChange
Toronto dominion bank-3.00
Nelson, van denburg & campbell wealth management group-14.00
Global retirement partners-19.00
Innealta capital-28.00
Northwestern mutual wealth management-39.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20241855.11%82,651,760-6.09%1060.82%96-6.80%5414.89%
Jun 30, 2024176-1.68%88,008,8780.38%1130.88%10310.75%47-7.84%
Mar 31, 20241792.29%87,677,4492.46%1130.91%933.33%51-5.56%
Dec 31, 2023175-7.41%85,573,7133.91%1110.96%90-15.09%548.00%
Sep 30, 20231898.62%82,354,299-0.97%1070.90%106-4.50%5021.95%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Delaware Small Cap Core I3.45M4.42%-21.39K
Macquarie Small Cap Core I3.45M3.97%-
Vanguard Total Stock Mkt Idx Inv2.71M3.12%-
Aviva Investors GlConvtAbsRet I USD Acc2.20M2.88%-229.35K
iShares Russell 2000 ETF2.03M2.33%-7.78K
SPDR® S&P Biotech ETF2.01M2.31%-23.50K
HBM Healthcare Investments AG Ord1.50M1.96%-
Pictet Biopharmaceutical Mother1.09M1.43%5.28K
Vanguard Institutional Extnd Mkt Idx Tr1.20M1.38%155.91K
Vanguard Strategic Equity Inv972.18K1.25%94.33K

Recent Insider Transactions

DateNameRoleActivityValue
Jan 22, 2025ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&DSell$47.42K
Jan 22, 2025Dube Eric M CHIEF EXECUTIVE OFFICERSell$208.92K
Jan 22, 2025REED ELIZABETH E SVP, GC & CORPORATE SECRETARYSell$47.42K
Jan 23, 2025Baynes Roy D.-Sell$320.00K
Jan 22, 2025Heerma Peter CHIEF COMMERCIAL OFFICERSell$30.00K

Insider Transactions Trends

DateBuySell
2024 Q4-4
2024 Q3-9
2024 Q2-1
2024 Q1-18
2023 Q4-1

TVTX Ownership FAQ

Who Owns Travere Therapeutics?

Travere Therapeutics shareholders are primarily institutional investors at 106.26%, followed by 0.65% insiders and -6.91% retail investors. The average institutional ownership in Travere Therapeutics's industry, Biotech Stocks , is 109.70%, which Travere Therapeutics falls below.

Who owns the most shares of Travere Therapeutics?

Travere Therapeutics’s largest shareholders are Blackrock (7.64M shares, 9.86%), Armistice capital (7.5M shares, 9.68%), and Deep track capital, lp (7.37M shares, 9.51%). Together, they hold 29.05% of Travere Therapeutics’s total shares outstanding.

Does Blackrock own Travere Therapeutics?

Yes, BlackRock owns 9.86% of Travere Therapeutics, totaling 7.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.84M$. In the last quarter, BlackRock decreased its holdings by -152K shares, a -1.95% change.

Who is Travere Therapeutics’s biggest shareholder by percentage of total assets invested?

Finepoint capital lp is Travere Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.15% of its assets in 1.78M Travere Therapeutics shares, valued at 14.6M$.

Who is the top mutual fund holder of Travere Therapeutics shares?

Delaware Small Cap Core I is the top mutual fund holder of Travere Therapeutics shares, with 4.42% of its total shares outstanding invested in 3.45M Travere Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools